Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease
Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure and limited treatment solutions that are unable to target any of the suspected causes. Increasing evidence suggests that one of the causes of neurodegeneration is the overproduction of amyloid beta (Aβ) and the in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2015-07-01
|
| Series: | AIMS Molecular Science |
| Subjects: | |
| Online Access: | http://www.aimspress.com/Molecular/article/349/fulltext.html |
| _version_ | 1818175546991837184 |
|---|---|
| author | Morgan Robinson Brenda Yasie Lee Zoya Leonenko |
| author_facet | Morgan Robinson Brenda Yasie Lee Zoya Leonenko |
| author_sort | Morgan Robinson |
| collection | DOAJ |
| description | Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure and limited treatment solutions that are unable to target any of the suspected causes. Increasing evidence suggests that one of the causes of neurodegeneration is the overproduction of amyloid beta (Aβ) and the inability of Aβ peptides to be cleared from the brain, resulting in self-aggregation to form toxic oligomers, fibrils and plaques. One of the potential treatment options is to target Aβ and prevent self-aggregation to allow for a natural clearing of the brain. In this paper, we review the drugs and drug delivery systems that target Aβ in relation to Alzheimer's disease. Many attempts have been made to use anti-Aβ targeting molecules capable of targeting Aβ (with much success in vitro and in vivo animal models), but the major obstacle to this technique is the challenge posed by the blood brain barrier (BBB). This highly selective barrier protects the brain from toxic molecules and pathogens and prevents the delivery of most drugs. Therefore novel Aβ aggregation inhibitor drugs will require well thought-out drug delivery systems to deliver sufficient concentrations to the brain. |
| first_indexed | 2024-12-11T20:02:01Z |
| format | Article |
| id | doaj.art-2056e6790afd49eaba7ec1118be23514 |
| institution | Directory Open Access Journal |
| issn | 2372-0301 |
| language | English |
| last_indexed | 2024-12-11T20:02:01Z |
| publishDate | 2015-07-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | AIMS Molecular Science |
| spelling | doaj.art-2056e6790afd49eaba7ec1118be235142022-12-22T00:52:30ZengAIMS PressAIMS Molecular Science2372-03012015-07-012333235810.3934/molsci.2015.3.332201503332Drugs and drug delivery systems targeting amyloid-β in Alzheimer's diseaseMorgan Robinson0Brenda Yasie Lee1Zoya LeonenkoDepartment of Biology, University of Waterloo, Waterloo, Ontario, CanadaDepartment of Biology, University of Waterloo, Waterloo, Ontario, CanadaAlzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure and limited treatment solutions that are unable to target any of the suspected causes. Increasing evidence suggests that one of the causes of neurodegeneration is the overproduction of amyloid beta (Aβ) and the inability of Aβ peptides to be cleared from the brain, resulting in self-aggregation to form toxic oligomers, fibrils and plaques. One of the potential treatment options is to target Aβ and prevent self-aggregation to allow for a natural clearing of the brain. In this paper, we review the drugs and drug delivery systems that target Aβ in relation to Alzheimer's disease. Many attempts have been made to use anti-Aβ targeting molecules capable of targeting Aβ (with much success in vitro and in vivo animal models), but the major obstacle to this technique is the challenge posed by the blood brain barrier (BBB). This highly selective barrier protects the brain from toxic molecules and pathogens and prevents the delivery of most drugs. Therefore novel Aβ aggregation inhibitor drugs will require well thought-out drug delivery systems to deliver sufficient concentrations to the brain.http://www.aimspress.com/Molecular/article/349/fulltext.htmlamyloidamyloid aggregationinhibitor drugsAlzheimer's diseasedrug delivery systemsblood brain barriernanotechnology |
| spellingShingle | Morgan Robinson Brenda Yasie Lee Zoya Leonenko Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease AIMS Molecular Science amyloid amyloid aggregation inhibitor drugs Alzheimer's disease drug delivery systems blood brain barrier nanotechnology |
| title | Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease |
| title_full | Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease |
| title_fullStr | Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease |
| title_full_unstemmed | Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease |
| title_short | Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease |
| title_sort | drugs and drug delivery systems targeting amyloid β in alzheimer s disease |
| topic | amyloid amyloid aggregation inhibitor drugs Alzheimer's disease drug delivery systems blood brain barrier nanotechnology |
| url | http://www.aimspress.com/Molecular/article/349/fulltext.html |
| work_keys_str_mv | AT morganrobinson drugsanddrugdeliverysystemstargetingamyloidbinalzheimersdisease AT brendayasielee drugsanddrugdeliverysystemstargetingamyloidbinalzheimersdisease AT zoyaleonenko drugsanddrugdeliverysystemstargetingamyloidbinalzheimersdisease |